235 related articles for article (PubMed ID: 37901214)
1. Targeting myeloid-derived suppressor cells with gemcitabine to enhance efficacy of adoptive cell therapy in bladder cancer.
Bazargan S; Bunch B; Ojwang' AME; Blauvelt J; Landin A; Ali J; Abrahams D; Cox C; Hall AM; Beatty MS; Poch M; Rejniak KA; Pilon-Thomas S
Front Immunol; 2023; 14():1275375. PubMed ID: 37901214
[TBL] [Abstract][Full Text] [Related]
2. Systemic and intravesical adoptive cell therapy of tumor-reactive T cells can decrease bladder tumor growth in vivo.
Bunch BL; Morse J; Asby S; Blauvelt J; Aydin AM; Innamarato P; Hajiran A; Beatty M; Poch M; Pilon-Thomas S
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33303579
[TBL] [Abstract][Full Text] [Related]
3. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
[TBL] [Abstract][Full Text] [Related]
4. Targeting myeloid-derived suppressor cells in combination with primary mammary tumor resection reduces metastatic growth in the lungs.
Bosiljcic M; Cederberg RA; Hamilton MJ; LePard NE; Harbourne BT; Collier JL; Halvorsen EC; Shi R; Franks SE; Kim AY; Banáth JP; Hamer M; Rossi FM; Bennewith KL
Breast Cancer Res; 2019 Sep; 21(1):103. PubMed ID: 31488209
[TBL] [Abstract][Full Text] [Related]
5. RS 504393 inhibits M-MDSCs recruiting in immune microenvironment of bladder cancer after gemcitabine treatment.
Mu XY; Wang RJ; Yao ZX; Zheng Z; Jiang JT; Tan MY; Sun F; Fan J; Wang X; Zheng JH; Wu K; Liu ZH
Mol Immunol; 2019 May; 109():140-148. PubMed ID: 30951933
[TBL] [Abstract][Full Text] [Related]
6. Reactive Myelopoiesis Triggered by Lymphodepleting Chemotherapy Limits the Efficacy of Adoptive T Cell Therapy.
Innamarato P; Kodumudi K; Asby S; Schachner B; Hall M; Mackay A; Wiener D; Beatty M; Nagle L; Creelan BC; Sarnaik AA; Pilon-Thomas S
Mol Ther; 2020 Oct; 28(10):2252-2270. PubMed ID: 32615068
[TBL] [Abstract][Full Text] [Related]
7. Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy.
Sasso MS; Lollo G; Pitorre M; Solito S; Pinton L; Valpione S; Bastiat G; Mandruzzato S; Bronte V; Marigo I; Benoit JP
Biomaterials; 2016 Jul; 96():47-62. PubMed ID: 27135716
[TBL] [Abstract][Full Text] [Related]
8. Topical and systemic immunoreaction triggered by intravesical chemotherapy in an N-butyl-N-(4-hydroxybutyl) nitorosamine induced bladder cancer mouse model.
Hori S; Miyake M; Tatsumi Y; Onishi S; Morizawa Y; Nakai Y; Tanaka N; Fujimoto K
PLoS One; 2017; 12(4):e0175494. PubMed ID: 28406993
[TBL] [Abstract][Full Text] [Related]
9. Combination of novel intravesical xenogeneic urothelial cell immunotherapy and chemotherapy enhances anti-tumor efficacy in preclinical murine bladder tumor models.
Huang CP; Wu CC; Shyr CR
Cancer Immunol Immunother; 2021 May; 70(5):1419-1433. PubMed ID: 33156394
[TBL] [Abstract][Full Text] [Related]
10. Dual depletion of myeloid-derived suppressor cells and tumor cells with self-assembled gemcitabine-celecoxib nano-twin drug for cancer chemoimmunotherapy.
Zhang X; Liang Q; Cao Y; Yang T; An M; Liu Z; Yang J; Liu Y
J Nanobiotechnology; 2024 Jun; 22(1):319. PubMed ID: 38849938
[TBL] [Abstract][Full Text] [Related]
11. [Double-mutated oncolytic adenovirus combined with gemcitabine for treating an orthotopic nude mouse model of bladder cancer].
Wang H; Liu Z; Wang ZP; Li FY; Zhao Y; Chen GP; Li DC
Zhonghua Zhong Liu Za Zhi; 2013 Jun; 35(6):412-7. PubMed ID: 24119899
[TBL] [Abstract][Full Text] [Related]
12. Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical response.
Dammeijer F; De Gooijer CJ; van Gulijk M; Lukkes M; Klaase L; Lievense LA; Waasdorp C; Jebbink M; Bootsma GP; Stigt JA; Biesma B; Kaijen-Lambers MEH; Mankor J; Vroman H; Cornelissen R; Baas P; Van der Noort V; Burgers JA; Aerts JG
EBioMedicine; 2021 Feb; 64():103160. PubMed ID: 33516644
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of tumor implantation by intravesical gemcitabine in a murine model of superficial bladder cancer.
Brocks CP; Büttner H; Böhle A
J Urol; 2005 Sep; 174(3):1115-8. PubMed ID: 16094076
[TBL] [Abstract][Full Text] [Related]
14. Temporal changes within the (bladder) tumor microenvironment that accompany the therapeutic effects of the immunocytokine NHS-IL12.
Morillon YM; Su Z; Schlom J; Greiner JW
J Immunother Cancer; 2019 Jun; 7(1):150. PubMed ID: 31186063
[TBL] [Abstract][Full Text] [Related]
15. Intravesical oncolytic virotherapy and immunotherapy for non-muscle-invasive bladder cancer mouse model.
Smelser WW; Wang J; Ogden KM; Chang SS; Kirschner AN
BJU Int; 2023 Sep; 132(3):298-306. PubMed ID: 36961272
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity.
Suzuki E; Kapoor V; Jassar AS; Kaiser LR; Albelda SM
Clin Cancer Res; 2005 Sep; 11(18):6713-21. PubMed ID: 16166452
[TBL] [Abstract][Full Text] [Related]
17. Visualization and quantification of
Hoffmann SHL; Reck DI; Maurer A; Fehrenbacher B; Sceneay JE; Poxleitner M; Öz HH; Ehrlichmann W; Reischl G; Fuchs K; Schaller M; Hartl D; Kneilling M; Möller A; Pichler BJ; Griessinger CM
Theranostics; 2019; 9(20):5869-5885. PubMed ID: 31534525
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of myeloid-derived suppressive cell function with all-trans retinoic acid enhanced anti-PD-L1 efficacy in cervical cancer.
Liang Y; Wang W; Zhu X; Yu M; Zhou C
Sci Rep; 2022 Jun; 12(1):9619. PubMed ID: 35688951
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice.
Le HK; Graham L; Cha E; Morales JK; Manjili MH; Bear HD
Int Immunopharmacol; 2009 Jul; 9(7-8):900-9. PubMed ID: 19336265
[TBL] [Abstract][Full Text] [Related]
20. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
